{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:59:04Z","timestamp":1788335944330,"version":"build-2803163510"},"reference-count":52,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2023,6,13]]},"abstract":"<jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Perfusion imaging has the potential to identify neurodegenerative disorders in a preclinical stage. However, to correctly interpret perfusion-derived parameters, the impact of perfusion modifiers should be evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>In this systematic review, the impact of acute and chronic intake of four acetylcholinesterase inhibitors (AChEIs) on cerebral perfusion in adults was investigated: physostigmine, donepezil, galantamine, and rivastigmine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Chronic AChEI treatment results in an increase of cerebral perfusion in treatment-responsive patients with Alzheimer\u2019s disease, dementia with Lewy bodies, and Parkinson\u2019s disease dementia in the frontal, parietal, temporal, and occipital lobes, as well as the cingulate gyrus. These effects appear to be temporary, dose-related, and consistent across populations and different AChEI types. On the contrary, further perfusion decline was reported in patients not receiving AChEIs or not responding to the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>AChEIs appear to be a potential perfusion modifier in neurodegenerative patients. More research focused on quantitative perfusion in both patients with and without a cholinergic deficit is needed to draw conclusions on whether AChEI intake should be considered when analyzing perfusion data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jad-221125","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:31:57Z","timestamp":1683678717000},"page":"1211-1221","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review"],"prefix":"10.1177","volume":"93","author":[{"given":"Paulien","family":"Moyaert","sequence":"first","affiliation":[{"name":"Ghent University","place":["Belgium"]},{"name":"Lawson Health Research Institute","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soetkin","family":"Beun","sequence":"additional","affiliation":[{"name":"Ghent University","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Achten","sequence":"additional","affiliation":[{"name":"Ghent University","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Clement","sequence":"additional","affiliation":[{"name":"Ghent University","place":["Belgium"]},{"name":"Ghent University Hospital","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp13X669374"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2343040197"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e3181a6bebc"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1980-57642011DN05040011"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000487233"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-015-0261-z"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000511233"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30365-3"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X17702156"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-132639"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_3_6_15_2","doi-asserted-by":"crossref","unstructured":"HigginsJPT Savovi\u0107J PageMJ ElbersRG SterneJAC (2019) Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions pp. 205-228.","DOI":"10.1002\/9781119536604.ch8"},{"key":"e_1_3_6_16_2","first-page":"39","article-title":"Physostigmine and tetrahydroaminoacridine treatment of Alzheimer\u2019s disease","volume":"149","author":"Gustafson L","year":"1993","unstructured":"GustafsonL (1993) Physostigmine and tetrahydroaminoacridine treatment of Alzheimer\u2019s disease. Acta Neurol Scand Suppl 149, 39\u201341.","journal-title":"Acta Neurol Scand Suppl"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)93028-N"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.1997.0296"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.06.417"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.23967"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2009.03.013"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000375527"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-017-9803-y"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11055-008-9077-3"},{"key":"e_1_3_6_25_2","first-page":"188","article-title":"Cerebral perfusional effects of 1-year rivastigmine treatment in Alzheimer disease: A case report","volume":"50","author":"Ettorre E","year":"2015","unstructured":"EttorreE, BersaniFS, ColellaF, ServelloA, MinichinoA, MegnaV, LiberatoreM, BiondiM, MariglianoV (2015) Cerebral perfusional effects of 1-year rivastigmine treatment in Alzheimer disease: A case report. Riv Psichiatr 50, 188\u2013191.","journal-title":"Riv Psichiatr"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(03)00229-6"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200201210-00020"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02848786"},{"key":"e_1_3_6_29_2","first-page":"P66","article-title":"IC-P-168: Detection of changes in cerebralblood flow perfusion following aricept \u00ae treatment in mild Alzheimer subjects","volume":"5","author":"Antuono P","year":"2009","unstructured":"AntuonoP, JonesJ, WuZ, McReaT, FranczakM, WardDB, LiSJ (2009) IC-P-168: Detection of changes in cerebralblood flow perfusion following aricept \u00ae treatment in mild Alzheimer subjects. Alzheimers Dement 5, P66\u2013P66.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-010-9108-x"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12818"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-8301.2011.00399.x"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2011.12.077"},{"key":"e_1_3_6_34_2","first-page":"1441","article-title":"Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer\u2019s disease","volume":"42","author":"Nakano S","year":"2001","unstructured":"NakanoS, AsadaT, MatsudaH, UnoM, TakasakiM (2001) Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer\u2019s disease. J Nucl Med 42, 1441\u20131445.","journal-title":"J Nucl Med"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2005.10.012"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-2457(02)00110-4"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000063576"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/1051228405001468"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-008-0401-y"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-019-00182-9"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03027378"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/jon199884249"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-007-0022-2"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000051241"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0117"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200212000-00012"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-006-0478-6"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/61.3.267"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2009.12.047"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh177"},{"key":"e_1_3_6_51_2","first-page":"292","article-title":"Prediction of treatment response to rivastigmine in Alzheimer\u2019s dementia","volume":"75","author":"Adler G","year":"2004","unstructured":"AdlerG, BrassenS, ChwalekK, DieterB, TeufelM (2004) Prediction of treatment response to rivastigmine in Alzheimer\u2019s dementia. J Neurol Neurosurg Psychiatry 75, 292\u2013294.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afm117"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.019"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-221125","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-221125","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-221125","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:41:06Z","timestamp":1781854866000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-221125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6,13]]}},"alternative-id":["10.3233\/JAD-221125"],"URL":"https:\/\/doi.org\/10.3233\/jad-221125","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]}}}